FDA Files Savara's MOLBREEVI Application for Rare Lung Disease with Priority Review
The FDA has filed Savara's biologics license application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis, granting Priority Review with a target action date of August 22, 2026.
The U.S. Food and Drug Administration has filed Savara Inc.'s biologics license application for MOLBREEVI, a potential treatment for autoimmune pulmonary alveolar proteinosis. The FDA granted Priority Review with a target action date of August 22, 2026 under the Prescription Drug User Fee Act.
Priority Review designation directs overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard review applications.
MOLBREEVI is a recombinant human granulocyte-macrophage colony-stimulating factor delivered through an investigational nebulizer system. The drug has received multiple regulatory designations including Fast Track, Breakthrough Therapy, and Orphan Drug status from the FDA.
The company plans to submit marketing authorization applications to the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency by the end of the first quarter of 2026. MOLBREEVI has been granted Orphan Drug Designation for the treatment of autoimmune PAP by the FDA and the EMA, as well as Innovation Passport and Promising Innovative Medicine designations by the UK's MHRA.
MOLBREEVI has the potential to be the first and only approved therapy for autoimmune PAP in the U.S. and Europe. The company believes the considerable body of data in the application demonstrates MOLBREEVI improves pulmonary gas transfer, quality of life, and the clinical symptoms associated with this rare and debilitating lung disease.
Autoimmune pulmonary alveolar proteinosis is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages.
Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by autoantibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue.
Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.
Savara is a clinical-stage biopharmaceutical company based in Langhorne, Pennsylvania, focused on developing treatments for rare respiratory diseases. The company resubmitted its BLA for MOLBREEVI with FUJIFILM Biotechnologies as the drug substance manufacturer, following a Refusal to File letter from the FDA that requested additional data.
Savara also amended its loan agreement with Hercules Capital, allowing access to up to $105 million in term loans, contingent on FDA approval of MOLBREEVI. The stock currently trades at $5.53 with analyst targets ranging from $9 to $16, reflecting optimism around the company's pipeline. Shares have delivered a 106% return over the past year.